Stem Cell Trials for Degenerative Disc Disease & Back Arthritis

Delivery Method:

• The stem cells are injected directly into the damaged disc in the lower back (intradiscal injection) together with hyaluronic acid.

The procedure involves:

• Inserting a needle directly into the damaged spinal disc.
• Injecting the stem cell and hyaluronic acid mixture into the disc itself (intradiscal injection).

The product contains approximately:

• 6 million allogeneic mesenchymal precursor cells.
• Mixed with hyaluronic acid (HA), which may help support the disc environment and keep the cells within the disc.
• Mesenchymal precursor cells are early-stage mesenchymal cells taken from healthy donor bone marrow and expanded in a laboratory before being used as treatment. Think of them as an early version of normal Mesenchymal Stem Cells.

Treatment Groups

• Rexlemestrocel-L + HA Group: Participants receive a single intradiscal injection of rexlemestrocel-L combined with hyaluronic acid.
• Comparator Group: Participants receive a sham control procedure using saline solution near the affected disc to simulate treatment.

Blinding:

• Double-blind design.
• Participants and investigators assessing outcomes do not know which treatment the participant received.

Duration:

• Participants are followed for up to 24 months after treatment.

Primary Outcomes (Efficacy & Safety)

Pain Reduction:

• Change in low back pain at 12 months using the Visual Analog Scale (VAS).
• VAS is a simple pain scale where patients rate pain from 0 (no pain) to 100 (worst pain imaginable).

Safety:

• Researchers will track adverse events and serious adverse events for up to 24 months after treatment.

Secondary Outcomes (Function, Quality of Life & Opioid Use)

Functional Improvement:

• Change in Oswestry Disability Index (ODI) score at 12 months.
• ODI measures how much back pain affects daily life, including walking, sitting, lifting, work, and personal care. Higher scores mean greater disability.

Quality of Life:

• Change in EuroQol-5D (EQ-5D) score at 12 months.
• This questionnaire looks at mobility, pain, daily activities, anxiety/depression, and overall quality of life.

Pain Responders:

• Researchers will measure:
• How many participants achieve at least a 30% reduction in pain.
• How many participants achieve very low pain scores after treatment.

Combined Treatment Success:

• The study will assess how many participants achieve:
• At least a 30% reduction in pain.
• At least a 10-point improvement in ODI disability score.

Opioid Use:

• Researchers will also track how many participants are able to stop using opioid pain medications by 24 months after treatment.

Recruitment:

• The trial is currently recruiting across 39 sites in the United States, including California, Florida, Texas, New York, Georgia, Colorado, and several major academic spine centers.

Follow-up:

• Participants will be monitored for up to 24 months to assess pain relief, physical function, quality of life, safety, and opioid use after treatment.

Analysis:

• After all participants complete follow-up, researchers will analyze whether rexlemestrocel-L combined with hyaluronic acid performs better than the sham control procedure for chronic low back pain caused by degenerative disc disease.

Completion:

• Final study completion and analysis are currently expected in October 2027. The FDA has already reviewed Mesoblast’s earlier Phase 3 data. It indicated that if this second trial confirms strong pain reduction at 12 months, the results could support a future approval application. The FDA also said opioid reduction could potentially be included in the product label if the evidence is strong enough.

Delivery Method

• IDCT is delivered as a direct injection (intradiscal injection) into the damaged lumbar disc.

The procedure involves:

• Needle placement into the target disc
• Injection of the investigational cell therapy into a single degenerated lumbar disc.

The product contains:

• Approximately 9 million cultured donor-derived disc progenitor cells in 1 mL solution.

Cells Used

• The therapy uses cultured donor-derived disc progenitor cells taken from human intervertebral disc tissue.
• These cells are being used because they are already specialized toward spinal disc tissue and may be better suited to supporting repair inside damaged intervertebral discs.
• Unlike mesenchymal stem cells (MSCs), which can develop into multiple tissue types, disc progenitor cells are more tissue-specific and focused on spinal disc repair.

Treatment Groups

IDCT Group

• Participants receive:
• A single intradiscal injection of IDCT into the target disc.

Comparator Group

• Participants receive:
• A sham procedure involving needle insertion up to the annulus of the disc without therapeutic injection.

Blinding

• Double-blind design.
• Participants and most investigators do not know which treatment was given
• Only the injecting procedural team is unblinded.

Duration

• Participants are followed for:
• 52 weeks for the primary study period
• Plus an additional 52 weeks of follow-up
• Total follow-up duration: 104 weeks (2 years).

DiscGenics is investigating whether IDCT can safely reduce chronic lower back pain, improve mobility and daily function and help people avoid more invasive spinal procedures or surgery. The study will also use MRI scans over 2 years to assess whether the therapy can help preserve or improve the structure of damaged spinal discs over time.

Primary Outcomes (Pain, Function & Safety)

Pain Reduction

• Change in Visual Analogue Scale (VAS) low back pain score at 52 weeks.
• VAS is a simple pain scale where patients rate pain from:
• 0 = no pain
• 100 = worst pain imaginable.

Function Improvement

• Change in Oswestry Disability Index (ODI) score at 52 weeks.
• ODI is a questionnaire used to measure how back pain affects:
• Walking
• Sleeping
• Personal care
• Daily activities
• Overall physical function.

Safety Monitoring

• Researchers are monitoring:
• Moderate or severe adverse events
• Serious adverse events (SAEs)
• Disc-related complications including:
• Annular tears
• Disc herniation
• Disc extrusion/prolapse
• Discitis (disc infection).

Secondary Outcomes (Disc Structure, Quality of Life & Long-Term Outcomes)

Researchers will also evaluate:

MRI Disc Assessments

• MRI scans will assess:
• Disc volume
• Disc height
• Degeneration severity
• Modic changes
• Annular tears/fissures
• Herniation
• Endplate integrity over time.

Quality of Life

• The EQ-5D questionnaire will assess:
• Mobility
• Self-care
• Daily activities
• Pain/discomfort
• Anxiety/depression
• Overall health status.

Additional Measures Include

• Pain medication use
• Physical therapy and other supportive treatment use
• Treatment failure rates
• Need for additional invasive procedures or surgery
• Long-term adverse events.

Recruitment

• The trial is currently recruiting across 14 clinical sites in the United States

Follow-up

• Participants will be monitored for 104 weeks to assess:
• Low back pain
• Physical function
• Disc structure changes on MRI
• Safety and complication rates.

Analysis

• After all participants complete follow-up, researchers will analyze whether IDCT performs better than the sham procedure for improving pain, disability and disc-related outcomes in lumbar degenerative disc disease.

Completion

• Final study completion and analysis are currently expected in November 2028.

Delivery Method:

• CELZ-201-DDT is delivered via ultrasound-guided intramuscular injections.

The procedure involves:

• Intramuscular injections into the muscles alongside the lumbar spine
• Six total injections
• Three injections on each side of the lower back
• Ultrasound guidance to help accurately place the injections.

Cells Used:

• Donor-derived (allogeneic) perinatal tissue derived cells collected from umbilical cord-related tissue.
• The cells are expanded and developed as an “off-the-shelf” cell therapy designed to provide a standardized treatment product across patients.

Dose Groups:

• The study is testing several different dose levels:
• Low Dose: 6 million cells
• Medium Dose: 30 million cells
• High Dose: 60 million cells
• Expanded High Dose: 120 million cells.

Treatment Groups

CELZ-201-DDT Groups:

• Participants receive one of the CELZ-201-DDT dose levels.

Placebo Group:

• Participants receive placebo injections instead of the investigational treatment.

Blinding:

• Double-blind design.
• Participants and investigators do not know which treatment the participant received.

Duration:

• Participants are followed for up to 12 months for efficacy assessments and longer for overall study completion.

What They’re Looking For

Primary Outcome (Safety)

Safety and Tolerability:

• Researchers are mainly assessing safety by monitoring for serious adverse events or severe side effects over 6 months.

Secondary Outcomes (Pain, Mobility & Medication Use)

Pain Reduction:

• Researchers will assess changes in pain using the Visual Analogue Scale (VAS).
• VAS is a simple pain scale where patients rate pain from 0 to 10.

Disability and Mobility:

• Researchers will assess disability using the Oswestry Disability Index (ODI).
• ODI is a questionnaire used to measure how much lower back pain affects daily activities and mobility.

Pain Medication Use:

• Researchers will also assess whether participants reduce their use of pain medications after treatment.

Next Steps

Recruitment:

• The study is currently recruiting in Florida, United States.

Follow-up:

• Participants will be monitored to assess safety, pain relief, mobility, disability, and pain medication usage after treatment.

Analysis:

• After follow-up is completed, researchers will analyze whether CELZ-201-DDT appears safe and whether it shows signs of improving chronic lower back pain and function compared to placebo injections.

Completion:

• Final study completion is currently expected in May 2027.

Delivery method:

• Each patient receives a single injection of 40 million cells directly into the damaged disc.
• Control patients undergo the same procedure but receive a saline (placebo) injection instead.
• This is a randomized, double-blind trial, meaning neither the patients nor doctors know who gets the real treatment.

Cell Used

• Type: Mesenchymal stem cells (MSCs)
• Source: Patient’s own bone marrow (autologous BMAC)
• Culture: The cells were cultured in low-oxygen (hypoxic) conditions to better match the environment inside spinal discs, which helps improve their survival and activity after injection. This approach is not standard. Most stem cell therapies grow cells in normal oxygen levels, making BioRestorative’s method a unique and potentially more effective strategy
• Preparation: The cells were mixed with the patient’s own platelet lysate, which is a part of their blood rich in natural healing proteins. This is unusual, most treatments use additives from donors or plain saline, so using the patient’s own blood makes it more personalized and may reduce the risk of side effects
• Dose: One injection of 40 million cells

Timepoint

• % with >50% Improvement in Function (ODI)
• % with >50% Reduction in Pain (VAS)
• Patients with >50% Improvement in Both

Week 12

• 67.6%
• 73.8%
• 5 out of 25

Week 26

• 74.0%
• 76.9%
• 6 out of 15

Week 52

• 74.6%
• 72.4%
• 8 out of 10

Week 104

• 75.1%
• 68.5%
• 2 out of 4

Most patients felt much better after treatment. By 1 year, over 70% had less pain and could move better and 8 out of 10 improved in both areas.

Success in this study was measured by how much pain went down and how much physical function improved. Not by whether the discs themselves were regenerated on scans.

Next Steps

• Complete enrollment of all 99 patients
• Collect full 52-week data for all subjects (needed for FDA review)
• Continue 2-year follow-up to confirm long-term safety and durability
• Submit results to the FDA for potential approval (BLA)
• Publish peer-reviewed data (no publication yet — only ISSCR conference presentation)
• Explore additional indications, such as cervical disc disease, already approved for testing

Delivery Method:

• The BM-MSCs are injected directly into the degenerated lumbar disc using imaging guidance. (intradiscal Injection)

Cells Used:

• Donor-derived (allogeneic) bone marrow mesenchymal stromal cells (BM-MSCs)
• The cells are culture-expanded in a laboratory before treatment
• This means the cells are multiplied outside the body to increase the cell dose before injection.

Dose Used:

• Approximately 20 million BM-MSCs
• Dose range: 20 ± 5 million cells
• Suspended in 2 mL of transport solution before injection.

Treatment Groups

BM-MSC Group:

• Participants receive intradiscal BM-MSC injections into the affected lumbar disc.

Sham Procedure Group:

• Participants receive a sham procedure involving local anesthetic injections near the affected spinal segment instead of stem cell injections into the disc itself.

Blinding:

• Triple-blind design.
• Participants, care providers, and investigators do not know which treatment the participant received during the study.

Duration:

• Participants are followed for up to 24 months for pain, disability, MRI, safety, and quality of life assessments.

What They’re Looking For

Primary Outcomes (Pain & Function)

Pain Reduction:

• Researchers are assessing whether participants achieve meaningful pain reduction using the Visual Analogue Scale (VAS).
• VAS is a pain scale where patients rate pain from 0 to 100:
• 0 = no pain
• 100 = worst pain imaginable.

Functional Improvement:

• Researchers are also measuring disability and daily function using the Oswestry Disability Index (ODI).
• ODI is a questionnaire commonly used to assess how much lower back pain affects mobility and everyday activities.

Secondary Outcomes (MRI, Quality of Life & Safety)

MRI Disc Assessment:

• Researchers are evaluating changes in disc structure and disc quality using MRI scans.
• The MRI analysis looks at:
• Disc hydration/fluid content
• Glycosaminoglycan (GAG) content
• Degeneration grading
• Structural disc changes over time.

Quality of Life:

• Researchers are measuring quality of life and disability using:
• SF-36 questionnaires
• Patient global assessments
• Physician global assessments.

Pain Medication Use:

• Researchers are tracking whether participants reduce their use of pain medications after treatment.

Immune Monitoring:

• Researchers are also studying immune responses to the donor-derived MSCs, including monitoring for anti-HLA antibodies.

Safety:

• Researchers are monitoring for serious adverse events (SAEs) throughout the study.

Next Steps

Follow-up:

• Participants continue to be monitored for up to 24 months for pain, function, MRI changes, immune response, and safety outcomes.

Analysis:

• Researchers will analyze whether BM-MSC treatment improves chronic disc-related lower back pain and disability compared with the sham procedure.

Completion:

• Final study completion is currently expected in March 2026.

Delivery Method:

• The BM-MSCs are injected directly into the lumbar facet joints using fluoroscopic (X-ray) guidance. (Intra-articular facet joint injection)

Cells Used:

• Donor-derived (allogeneic) bone marrow mesenchymal stem cells (BM-MSCs)
• The cells are culture-expanded in a laboratory before treatment
• This means the cells are multiplied outside the body to increase the total cell dose before injection.

Dose Used:

• 10 million BM-MSCs per facet joint
• 2 facet joints treated
• Total dose: approximately 20 million BM-MSCs.

Treatment Groups

BM-MSC Group:

• Participants receive direct BM-MSC injections into the painful lumbar facet joints.

Placebo Group:

• Participants initially receive placebo DMSO injections instead of stem cells.

Crossover:

• After 6 months, placebo participants cross over and receive BM-MSC treatment.

Blinding:

• Triple-blind design.
• Participants, care providers, and investigators do not know which treatment the participant received during the blinded portion of the study.

Duration:

• Participants are followed for up to 24 months for pain, function, MRI, medication use, and safety assessments.

What They’re Looking For (Tab 3)

Primary Outcomes (Safety, Pain & Function)

Safety:

• Researchers are closely monitoring for adverse events and side effects throughout the study.

Pain & Function:

• Researchers are assessing:
• Pain levels
• Physical function
• Ability to work
• Use of narcotic pain medications
• Overall physical and mental health.

PROMIS-CAT:

• Researchers are using the PROMIS-CAT questionnaire system to evaluate physical, mental, and social health over time.

Secondary Outcomes (MRI Changes)

MRI Assessment:

• Researchers are evaluating structural changes in the lumbar facet joints using MRI scans.

Next Steps

Follow-up:

• Participants continue to be monitored for up to 24 months for pain, function, MRI changes, medication use, and safety outcomes.

Analysis:

• Researchers will analyze whether BM-MSC treatment improves chronic facet joint arthritis-related lower back pain compared with placebo treatment.

Completion:

• Final study completion is currently expected in July 2026.

Procedure and Dosage:

• Each patient received 2 intra articular injections into lumbar facet joints under fluoroscopic (X-ray) guidance.
• Each injection contained:
• 10 million cultured donor-derived BM-MSCs
• suspended in 1 mL Lactated Ringer’s solution.
• Total dose per patient:
• 20 million BM-MSCs.

Blinding:

• Open-label study (patients and researchers knew stem cells were being used).

Follow-up:

• Patients were followed for 24 months with:
• pain questionnaires
• physical function testing
• MRI scans
• blood safety testing.

Cell Preparation and Procedure:

BM-MSCs (Bone Marrow-Derived Mesenchymal Stem Cells):

• The stem cells came from a healthy 28-year-old donor.
• The donor bone marrow was:
• processed in a GMP-certified laboratory
• expanded in the lab (culture-expanded)
• cryopreserved and stored before use.
• The cells used in patients were:
• allogeneic (donor-derived)
• cultured/expanded
• Passage 3 BM-MSCs.

Primary Endpoint (Safety):

• No serious adverse events related to the stem cells were reported during the study.
• Researchers also reported:
• no signs of immune rejection
• no abnormal blood test findings related to treatment.

Pain Reduction (VAS Score):

• Researchers defined meaningful improvement as at least a 50% reduction in pain scores.
• Results:
• 75% of patients achieved this level of pain improvement at 6 months.
• 67% of patients maintained this level of pain improvement at 12, 18 and 24 months.
• Average pain scores also improved substantially over time.

Physical Function (PROMIS Physical Function):

• Researchers defined meaningful functional improvement as an increase of at least 2.3 points on the PROMIS Physical Function score.
• Results:
• Around 56% of patients achieved meaningful improvements in physical function throughout follow-up.

MRI Findings:

• MRI scans were used to assess:
• inflammation
• edema/swelling
• degeneration
• synovitis (joint inflammation)
• bone marrow changes in the facet joints.
• Results after 2 years:
• 5 patients showed improvement in facet joint degeneration on MRI.
• 3 patients showed no major change.
• 1 patient worsened.
• One MRI example in the paper showed:
• reduced capsular inflammation
• reduced edema
• improvement in facet joint synovitis severity over 24 months.

Mental Health and Quality of Life:

• Patients also reported improvements in:
• depression
• anxiety
• sleep
• fatigue
• social functioning.

How Cells Worked (Researcher’s View):

• The researchers explained that the BM-MSCs likely worked mainly through anti-inflammatory and healing signals rather than permanently turning into new spinal joint tissue.
• They proposed the cells:
• reduced inflammation inside the facet joints
• released bioactive healing molecules
• improved the local joint environment
• helped reduce pain signaling and joint irritation.
• The researchers specifically stated that the treatment effects were likely caused by:
• paracrine signaling
• immunomodulation
• trophic/healing effects
• rather than long-term engraftment or direct tissue replacement.
• The MRI findings suggested reduced inflammation and degeneration in some joints, but the study did not prove full regeneration of the facet joints.

Adverse Events:

• No deaths related to treatment were reported.
• Three serious adverse events occurred during the study, including:
• knee replacement surgery
• spinal surgery for sciatica on the opposite side
• prostate cancer
• Researchers determined these were unrelated to the stem cell treatment.
• Common mild side effects included:
• injection site pain
• temporary stiffness
• headache
• localized soreness or discomfort.
• Most resolved with conservative treatment or over-the-counter medication.

Conclusion:

• This early Phase I trial suggests that cultured donor-derived bone marrow stem cells may help reduce chronic lower back pain caused by lumbar facet joint arthritis.
• Many patients experienced meaningful improvements in pain and physical function lasting up to 2 years, and some patients also showed improved MRI findings in the treated facet joints.
• The treatment appeared relatively safe in this small study, with no serious stem cell-related complications reported.
• However, this was a small open-label study without a placebo group, so larger randomized controlled trials are still needed to confirm whether the treatment truly works and how effective it is long term.

Procedure:

• Patients were randomly assigned into 3 groups:
• Rexlemestrocel-L alone
• Rexlemestrocel-L combined with hyaluronic acid (HA)
• Placebo saline injection
• The stem cell treatment involved approximately 6 million allogeneic mesenchymal precursor cells injected directly into the damaged lumbar disc.
• The HA group received the same stem cells mixed with hyaluronic acid before injection.

Blinding:

• Quadruple-blind (patients, investigators, care providers and outcome assessors did not know which treatment was given).

Follow-up:

• Patients were followed for up to 36 months after treatment.

Cell Preparation and Procedure:

Rexlemestrocel-L:

• An off the shelf allogeneic, bone marrow derived mesenchymal precursor cell product developed by Mesoblast.
• The cells were not taken from the patient. They were manufactured donor derived cells prepared in advance and injected directly into the spinal disc in a single procedure.
• Mesenchymal precursor cells are early-stage mesenchymal cells taken from healthy donor bone marrow and expanded in a laboratory before being used as treatment. Think of them as an early version of normal Mesenchymal Stem Cells.

Primary Endpoint (Overall Treatment Success):

• The primary endpoint required patients to meet all 3 conditions:
• At least 50% reduction in back pain
• At least 15-point improvement in disability (ODI score)
• No further spinal intervention at the treated level
• Patients also had to maintain these improvements at both 12 and 24 months.

Results:

• Rexlemestrocel-L alone: 26.7%
• Rexlemestrocel-L + HA: 33.5%
• Placebo: 31.3%
• The study did not meet the predefined statistical threshold for success.

Pain Reduction (VAS Scores):

• The strongest findings were seen in the rexlemestrocel-L + HA group.
• At 12 months:
• Rexlemestrocel-L + HA patients improved by -27.4 points
• Placebo improved by -19.0 points
• Difference versus placebo: -8.4 points
• Statistically significant (P = 0.0162)
• At 24 months:
• Rexlemestrocel-L + HA improved by -25.9 points
• Placebo improved by -18.3 points
• Difference versus placebo: -7.6 points
• Statistically significant (P = 0.0426)
• The rexlemestrocel-L alone group generally did not outperform placebo significantly.

Functional Improvement (ODI):

• The treatment did not clearly improve disability or physical function better than placebo.
• Functional responder rates:
• Rexlemestrocel-L alone: 37.8%
• Rexlemestrocel-L + HA: 40.9%
• Placebo: 41.3%

Adverse Events:

• No deaths were reported.
• Serious adverse events:
• Rexlemestrocel-L alone: 12.1%
• Rexlemestrocel-L + HA: 11.7%
• Placebo: 7.7%
• Most common non-serious side effects included:
• Back pain
• Joint pain
• Pain in extremities
• Muscle spasms
• Numbness or tingling sensations
• Some serious medical events occurred in the treatment groups, including cardiac events and neurological events, although the study itself did not establish that the stem cells caused these events.

Conclusion:

• This Phase III trial showed mixed results. The study failed its original primary endpoint, meaning it was not considered a fully successful Phase III trial under the original FDA study design. However, the rexlemestrocel-L + HA group showed statistically significant improvements in chronic low back pain at both 12 and 24 months compared to placebo.
• The treatment appeared to reduce pain more effectively than improve physical function.
• The group that received rexlemestrocel-L combined with hyaluronic acid (HA) showed statistically significant pain reduction. The FDA later agreed that pain reduction at 12 months could potentially support approval in a new Phase III trial.
• Mesoblast has since launched another Phase III confirmatory trial to see if rexlemestrocel-L + HA can reduce chronic low back pain at 12 months and reduce opioid use.

Procedure

• Patients were randomly split into:
• Stem cell injection group
• Sham/placebo procedure group.
• The sham group underwent a fake procedure designed to mimic treatment without actually injecting the spinal discs.

Delivery Method

• The cells were injected directly into the degenerated lumbar discs using fluoroscopic (X-ray) guidance. (intradiscal injections)

Cells Used

• Autologous Bone Marrow-Derived MSCs
• Meaning:
• The stem cells came from each patient’s own bone marrow
• Bone marrow was taken from the back of the pelvis (hip bone).

Dosage

• Approximately:
• 15 million expanded MSCs per disc injected.
• Some patients had:
• 1 disc treated
• 2 discs treated
• 3 discs treated.

Culture Method

Cell Expansion

• The cells were:
• Expanded in a GMP-certified laboratory
• Cultured for around 3 weeks before injection.
• The researchers specifically expanded and purified MSCs rather than simply concentrating bone marrow like BMAC procedures.

Cell Testing

• Before injection, the cells were tested for:
• Viability (whether the cells were alive)
• Sterility/contamination
• Normal chromosomes (karyotype testing)
• MSC identity markers:
• CD73
• CD90
• CD105
• Low contamination with blood/immune cells.
• Some patients were excluded because:
• Their cells developed chromosomal abnormalities during expansion
• Or the sample became contaminated.

Did They Modify the Cells to Help Survival?

• No.
• The researchers did NOT:
• Hypoxia-condition the cells
• Genetically modify them
• Use hydrogels/scaffolds
• Add special survival-enhancing engineering.
• The cells were injected in a saline/albumin solution.
• The paper actually discusses that spinal discs are a very harsh environment for cells because they have:
• Low oxygen
• Low nutrients
• Acidic pH
• Inflammation.
• The researchers suggest this may reduce stem cell survival and effectiveness.

Follow-up duration

• ⚠️ Preliminary 6-month results only.
• The final longer-term outcomes are still pending.

Primary Outcome: VAS Pain Score

• (VAS = a 0–100 pain scale where lower numbers mean less pain)

Stem Cell Group:

• Pain dropped from 54.5 → 42.5

Sham Group:

• Pain dropped from 60.8 → 42.5.
• ➡️ Both groups improved.
• ➡️ BUT the stem cell group was not significantly better than placebo at 6 months.

Disability (ODI Score)

• The sham group actually showed slightly better disability improvements overall.
• Again:
• no significant clinical advantage for stem cells at 6 months.

MRI Structural Changes

• MRI scans showed some structural improvements in the stem cell group:
• Disc height slightly increased
• Some early signs of improved hydration/structure
• Temporary improvement in degeneration grading at 3 months.
• The sham group did not show the same disc height improvements.
• However:
• These MRI improvements did not clearly translate into superior pain relief yet.

Safety

• The treatment appeared relatively safe overall.
• Reported issues included:
• Temporary worsening of back pain after injection
• One allergic skin rash
• No major infections or deaths.

How the Cells Worked

• The researchers believe the cells likely worked mainly through:
• Anti-inflammatory signaling
• Supporting the disc environment
• Stimulating repair processes.
• There was no proof the cells rebuilt fully normal discs.
• The paper also notes that:
• structural regeneration and pain relief may not always directly match.

What We Don’t Know

• Whether the MRI improvements will eventually translate into better pain relief over longer follow-up
• Whether 12-month or longer outcomes may look different
• How many injected cells actually survived long-term inside the discs
• Whether younger donor cells or engineered MSCs may work better
• Whether patients with earlier-stage degeneration may respond more strongly.

Researchers’ Conclusions

• The researchers concluded that:
• Expanded autologous bone marrow MSC injections into degenerated spinal discs appear relatively safe.
• The treatment may produce measurable structural changes on MRI.
• HOWEVER, at 6 months, the stem cell treatment was not clearly better than placebo for reducing pain or disability.
• Longer-term follow-up is needed before determining whether these regenerative changes lead to meaningful clinical benefit.

What they’re trying to find out

• Whether stem cell therapy is effective for treating chronic discogenic back pain and degenerative disc disease.
• Whether MSC injections can:
• Reduce pain
• Improve physical function
• Help repair damaged spinal discs
• Improve MRI findings such as disc hydration and disc height
• Which types of stem cells and preparation methods appear most promising.
• Whether stem cells work mainly by:
• Becoming new disc tissue directly
• OR
• Sending out healing and anti-inflammatory signals that improve the disc environment.

1. Effectiveness:

• Most studies reported improvements in:
• Lower back pain
• Physical function
• Daily activity levels
• Disability scores.
• The most commonly used measures were:
• VAS (Visual Analogue Scale for pain)
• ODI (Oswestry Disability Index: a tool measuring how much back pain affects daily life).
• Across the studies:
• ODI disability scores improved significantly
• VAS pain scores also improved significantly after treatment.
• Some MRI scans showed:
• Increased disc hydration (more water content inside the disc)
• Preservation or improvement of disc height
• Reduced disc bulging/protrusion in some patients.
• However:
• One randomized trial found no major difference between stem cell treatment and saline placebo injections.

2. Mechanism of Action:

• The researchers believe MSCs mainly help by:
• Reducing inflammation
• Reducing harmful tissue breakdown (catabolism)
• Inhibiting pain-signaling nerve activity (nociceptors)
• Supporting repair of damaged disc tissue.
• Rather than simply replacing the damaged disc directly, MSCs appear to improve the healing environment inside the disc.
• The review also discusses “cross-talk” between injected MSCs and the disc’s native cells, especially involving TGF-beta signaling pathways important for tissue repair.

3. Stem Cell Source Comparison:

• Bone Marrow MSCs (BM-MSCs):
• Most commonly studied
• Generally showed encouraging pain and function improvements.
• Bone Marrow Concentrate (BMAC/BMC):
• Used in several studies
• Considered less manipulated than culture-expanded MSCs
• Some studies reported benefits, but results varied.
• Adipose-Derived MSCs:
• Showed promising safety and symptom improvements in early studies.
• Umbilical Cord MSCs:
• Small studies suggested encouraging results
• Researchers noted their low immunogenicity (less likely to trigger immune rejection).
• Allogeneic (Donor) MSCs:
• Appeared safe without major immune complications
• One paper suggested they may produce smaller healing effects compared to autologous MSCs.
• Juvenile Chondrocyte Products:
• Early safety and symptom improvements reported
• Limited evidence available.

4. Cell Culture & Preparation Insights:

• The studies used very different preparation methods, including:
• Culture-expanded MSCs
• Non-cultured BMAC approaches
• Hypoxic culture conditions (low oxygen lab environments)
• Co-culture systems using native disc cells
• Different carrier substances like:
• Hyaluronic acid
• Platelet lysate
• Saline
• Fibrin
• Collagen sponges.
• The review notes that:
• Oxygen conditions during cell culture may affect outcomes
• Growth factors such as TGF-β, GDF5, and GDF6 may influence how MSCs behave and repair disc tissue.
• However, the review does not directly prove that cultured MSCs are superior to non-cultured approaches because the studies were too different to compare properly.

5. Safety:

• MSC therapies were generally safe across the reviewed studies.
• Reported side effects were usually mild, including:
• Temporary injection-site pain
• Pain flare-ups treated with NSAIDs or opioids.
• Only 4 out of 303 patients later required surgery because stem cell therapy failed to relieve symptoms.
• No major tumor formation or severe immune complications were reported.
• However, the review notes that:
• Leakage of MSCs outside the disc could potentially lead to unwanted bone formation (osteophytes).

6. Limitations Across Trials:

• The researchers repeatedly state that the evidence is still limited because:
• Most studies were small
• Many were not randomized controlled trials
• Some studies included only a few patients
• Follow-up periods varied significantly
• Different scoring systems and MRI methods were used
• Cell preparation methods differed substantially between studies.
• The review also notes:
• Lack of standardized protocols
• Missing data in several studies
• Difficulty comparing results directly because every study used different methods.

What they concluded

• MSC therapy appears safe and promising for treating chronic discogenic back pain and degenerative disc disease.
• Many studies showed:
• Reduced pain
• Improved physical function
• Potential signs of disc repair on MRI
• The researchers believe the main benefit likely comes from:
• Anti-inflammatory signaling
• Reducing harmful degeneration
• Supporting tissue repair processes
• Rather than simply replacing damaged tissue directly.
• However:
• The evidence is still early
• Studies are highly variable
• There is not enough standardized data to determine the best:
• Cell source
• Dose
• Culture method
• Injection protocol.
• The researchers state there is a need for:
• Larger randomized controlled trials
• Longer follow-up studies
• Standardized treatment methods
• Better comparison between different stem cell approaches.